Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2231010 | 0.99 | KMT2A (0.44) | KMT2AMEN1LMNATSHRALOX12 | |
| SCHEMBL636937 | 0.92 | TAAR1 (0.43) | KMT2AMEN1LMNATSHRALOX12 | |
| SCHEMBL636954 | 0.87 | MGLL (0.38) | KMT2AMEN1LMNATAAR1MGLL | |
| SCHEMBL637631 | 0.87 | MGLL (0.38) | KMT2AMEN1LMNATAAR1MGLL | |
| SCHEMBL637967 | 0.87 | MGLL (0.38) | KMT2AMEN1LMNATAAR1MGLL | |
| SCHEMBL641010 | 0.87 | MGLL (0.38) | KMT2AMEN1LMNATAAR1MGLL | |
| SCHEMBL637517 | 0.86 | MGLL (0.42) | KMT2AMGLLBCHELIPE | |
| SCHEMBL917276 | 0.86 | TAAR1 (0.45) | KMT2AMEN1LMNATSHRALOX12 | |
| SCHEMBL917319 | 0.86 | MGLL (0.39) | KMT2AMEN1LMNATAAR1MGLL | |
| SCHEMBL916906 | 0.84 | TAAR1 (0.43) | KMT2AMEN1LMNATSHRALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385014-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | ARBOR PHARMACEUTICALS, LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180258032-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | ARBOR PHARMACEUTICALS, LLC | 2018-09-13 | — | — | US | disclosed |
| US-9944592-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170190657-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| EP-1660440-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20110021571-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20090234138-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS | XENOPORT, INC. | 2009-09-17 | — | — | US | disclosed |
| US-7572830-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080096960-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7300956-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070054945-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-7109239-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050107334-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385014-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | KMT2A 2442/4885MEN1 4486/4885LMNA 3875/4885 |
| US-20180258032-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | KMT2A 2442/4885MEN1 4486/4885LMNA 3875/4885 |
| US-20080096960-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | KMT2A 2442/4885MEN1 4486/4885LMNA 3875/4885 |
| US-20170190657-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | KMT2A 2442/4885MEN1 4486/4885LMNA 3875/4885 |
| US-20070054945-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | KMT2A 2442/4885MEN1 4486/4885LMNA 3875/4885 |
| US-20090234138-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS | APEH, ABAT, GABARAPL1 | KMT2A 2415/4885MEN1 4558/4885LMNA 3907/4885 |
| US-20110021571-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | KMT2A 2442/4885MEN1 4486/4885LMNA 3875/4885 |
| US-20050107334-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | KMT2A 2442/4885MEN1 4486/4885LMNA 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.